Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.3
3.8
Journals
Viruses
Special Issues
Viral Hepatitis and Liver Diseases
share announcement

Viral Hepatitis and Liver Diseases

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1219

Special Issue Editor

Dr. Carlo Smirne

E-Mail Website
Guest Editor
Associate Professor of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy
Interests: viral hepatitis; epidemiology of hepatitis C; hepatitis C treatment; hepatitis B; liver fibrosis; liver cirrhosis; hepatocellular carcinoma; autoimmune hepatitis; nonalcoholic steatohepatitis

Special Issue Information

Dear Colleagues,

Viral hepatitis is defined as an inflammation of the liver caused by viral pathogens that may cause severe hepatic disease. Its long-term sequelae, especially hepatocellular carcinoma and hepatic failure, have been recognized as serious problems in all parts of the world, particularly in the Asia–Pacific region, Africa, Latin America and Southern Europe. In fact, the burden of viral hepatitis remains substantial—both global and liver-specific—despite recent advances in antiviral therapy and effective measures to prevent infection at least for some viral types. The most common hepatitis viruses are types A, B, C, D and E (commonly referred to as HAV, HBV, HCV, HDV and HEV). However, many other viruses can lead to viral hepatitis, including human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein–Barr virus (EBV), herpes simplex virus (HSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and flaviviruses. Even though their effects on the liver and the symptoms they produce can be similar, the severity and duration of the disease are determined by the specific virus that caused it.

This Special Issue of Viruses welcomes original research, short communications and review articles that will contribute to an improved understanding of aspects such as the epidemiology of new emerging viruses causing liver diseases; new, viral-hepatitis-related molecular mechanisms of the immune response and of liver damage (including, but not limited to, liver fibrosis and hepatocellular carcinoma); and other relevant topics relating to viruses with proven liver toxicity (such as cutting-edge developments in their diagnosis, transmission or therapeutics).

Dr. Carlo Smirne
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic viral infection
  • viral hepatitis
  • liver fibrosis
  • hepatocellular carcinoma
  • hepatitis B virus
  • hepatitis C virus
  • hepatitis delta virus co-infection
  • hepatitis E virus
  • flavivirus
  • molecular mechanisms
  • epidemiological investigations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 880 KiB  
Article
Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO’s Targets in Ontario, Canada
by Yeva Sahakyan, Aysegul Erman, William W. L. Wong, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong and Beate Sander
Viruses 2024, 16(8), 1224; https://doi.org/10.3390/v16081224 - 31 Jul 2024
Viewed by 901
Abstract
Background: The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the “HCV care-cascade” is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the “HCV care-cascade” to [...] Read more.
Background: The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the “HCV care-cascade” is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the “HCV care-cascade” to achieve the WHO’s HCV elimination targets in Ontario, Canada. Methods: By employing a decision analytic model, we projected the quality-adjusted life years (QALYs) and healthcare costs for individuals with HCV in Ontario. We increased RNA testing and treatment rates to 98%, followed by increasing antibody testing uptake until we achieved the WHO’s mortality target (i.e., a 65% reduction in liver-related mortality by 2030 vs. 2015). Results: Without scaling up by 2030, the expected QALYs and costs per person were 9.156 and CAD 48,996, respectively. Improved RNA testing and treatment rates reduced liver-related deaths to 3.3/100,000, a 57% reduction from 2015. Further doubling the antibody testing rates can achieve the WHO’s mortality target in 2035, but not in 2030. Compared to the status quo, such program would be cost-effective considering a 50,000 CAD/QALY gained threshold if annual implementation costs stayed under 2.3 M CAD/100,000 people. Conclusions: Doubling the antibody testing rates, along with increased RNA testing and treatment rates, showed promise in meeting the WHO’s goals by 2035. Full article
(This article belongs to the Special Issue Viral Hepatitis and Liver Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop